DE60045075D1 - Anti-epha2 antikörper als krebsdiagnostikum - Google Patents

Anti-epha2 antikörper als krebsdiagnostikum

Info

Publication number
DE60045075D1
DE60045075D1 DE60045075T DE60045075T DE60045075D1 DE 60045075 D1 DE60045075 D1 DE 60045075D1 DE 60045075 T DE60045075 T DE 60045075T DE 60045075 T DE60045075 T DE 60045075T DE 60045075 D1 DE60045075 D1 DE 60045075D1
Authority
DE
Germany
Prior art keywords
cancer diagnostic
epha2
epha2 antibody
kits
overexpressed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60045075T
Other languages
English (en)
Inventor
Michael Scott Kinch
Nicole Dodge Zantek
Katherine E Kilpatrick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
University of North Carolina at Chapel Hill
Purdue Research Foundation
University of North Carolina System
Original Assignee
Glaxo Group Ltd
University of North Carolina at Chapel Hill
Purdue Research Foundation
University of North Carolina System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd, University of North Carolina at Chapel Hill, Purdue Research Foundation, University of North Carolina System filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DE60045075D1 publication Critical patent/DE60045075D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE60045075T 1999-08-17 2000-08-17 Anti-epha2 antikörper als krebsdiagnostikum Expired - Lifetime DE60045075D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14925999P 1999-08-17 1999-08-17
PCT/US2000/022669 WO2001012840A2 (en) 1999-08-17 2000-08-17 Anti-epha2 antibodies as a cancer diagnostic

Publications (1)

Publication Number Publication Date
DE60045075D1 true DE60045075D1 (de) 2010-11-18

Family

ID=22529464

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60045075T Expired - Lifetime DE60045075D1 (de) 1999-08-17 2000-08-17 Anti-epha2 antikörper als krebsdiagnostikum

Country Status (8)

Country Link
EP (2) EP2312316A1 (de)
JP (3) JP4948728B2 (de)
AT (1) ATE483978T1 (de)
AU (1) AU785445C (de)
CA (1) CA2382655A1 (de)
DE (1) DE60045075D1 (de)
ES (1) ES2357296T3 (de)
WO (1) WO2001012840A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927203B1 (en) 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
US7192698B1 (en) 1999-08-17 2007-03-20 Purdue Research Foundation EphA2 as a diagnostic target for metastatic cancer
MXPA02009454A (es) 2000-03-31 2003-04-10 Purdue Research Foundation Metodo de tratamiento usando conjugados ligando-inmunogeno.
US7101976B1 (en) 2000-09-12 2006-09-05 Purdue Research Foundation EphA2 monoclonal antibodies and methods of making and using same
AU2002314433A1 (en) * 2001-07-02 2003-01-21 Licentia Ltd. Ephrin-tie receptor materials and methods
ATE451935T1 (de) * 2001-09-28 2010-01-15 Purdue Research Foundation Behandlungsverfahren mit liganden- immunogenkonjugaten
WO2003040304A2 (en) * 2001-11-09 2003-05-15 Neuronova Ab Method of proliferation in neurogenic regions
EP2075256A2 (de) 2002-01-14 2009-07-01 William Herman Gezielte Liganden
CA2485548A1 (en) * 2002-05-10 2004-02-19 Purdue Research Foundation Epha2 agonistic monoclonal antibodies and methods of use thereof
AU2003243228B2 (en) * 2002-05-10 2009-03-26 Medimmune, Llc EphA2 monoclonal antibodies and methods of use thereof
EP1505999A4 (de) 2002-05-23 2009-07-08 Purdue Research Foundation Niedermolekulare protein-tyrosinphosphatase (lmw-ptp) als diagnostisches und therapeutisches target
WO2004101764A2 (en) * 2003-05-13 2004-11-25 Chiron Corporation Methods of modulating metastasis and skeletal related events resulting from metastases
AU2004281834A1 (en) * 2003-10-15 2005-04-28 Cerus Corporation Listeria-based EphA2 vaccines
JP2008510008A (ja) 2004-08-16 2008-04-03 メディミューン，インコーポレーテッド 抗体依存性細胞性細胞傷害活性が増強されたインテグリンアンタゴニスト
ZA200707275B (en) * 2005-02-04 2009-01-28 Raven Biotechnologies Inc Antibodies that bind to EphA2 and methods of use thereof
WO2007092299A2 (en) 2006-02-03 2007-08-16 Purdue Research Foundation Targeted conjugates and radiation
RU2525133C2 (ru) 2007-08-30 2014-08-10 Дайити Санкио Компани, Лимитед Антитело к epha2
JP5875054B2 (ja) * 2013-02-13 2016-03-02 国立大学法人 東京大学 がんの検査方法及び検査用キット
JP6069806B2 (ja) * 2013-02-13 2017-02-01 国立大学法人 東京大学 がんの検査方法及び検査用キット
JP6399013B2 (ja) * 2016-02-18 2018-10-03 トヨタ自動車株式会社 化学蓄熱器の制御装置
JP6729917B2 (ja) * 2016-08-19 2020-07-29 国立大学法人 東京大学 ＥｐｈＡ２ Ｎ末端フラグメント抗体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU663727B2 (en) 1991-08-22 1995-10-19 Becton Dickinson & Company Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy
US5457048A (en) * 1993-12-03 1995-10-10 La Jolla Cancer Research Foundation Eph-related tyrosine kinases, nucleotide sequences and methods of use
US5876949A (en) 1995-05-31 1999-03-02 The Trustees Of The University Of Pennsylvania Antibodies specific for fragile X related proteins and method of using the same

Also Published As

Publication number Publication date
AU785445B2 (en) 2007-06-14
EP2312316A1 (de) 2011-04-20
JP4948728B2 (ja) 2012-06-06
WO2001012840A2 (en) 2001-02-22
JP2007291140A (ja) 2007-11-08
EP1210603A2 (de) 2002-06-05
AU6784300A (en) 2001-03-13
AU785445C (en) 2008-01-31
WO2001012840A3 (en) 2001-05-03
WO2001012840B1 (en) 2001-09-27
CA2382655A1 (en) 2001-02-22
ATE483978T1 (de) 2010-10-15
JP2003507023A (ja) 2003-02-25
ES2357296T3 (es) 2011-04-25
EP1210603B1 (de) 2010-10-06
JP2012103264A (ja) 2012-05-31

Similar Documents

Publication Publication Date Title
DE60045075D1 (de) Anti-epha2 antikörper als krebsdiagnostikum
EP1585966B8 (de) Behandlung von Krebs mit dem anti-ErbB2-Antikörper rhuMAb 2C4
WO2000052204A3 (en) Gene expression in bladder tumors
NZ597363A (en) Prognosis prediction for colorectal cancer
RU2005131842A (ru) Моноклональное антитело и продуцирующая его гибридома
DK1242060T3 (da) Behandling af metastatisk sygdom
WO2005113000A3 (en) Anti-cancer activity of an anti-thymidine kinase monoclonal antibody
CA2384579A1 (en) Early cancer tumor marker
ATE238555T1 (de) Krebsbehandlung
WO2001075177A3 (en) Tumor markers in ovarian cancer
WO2004056874A3 (en) Neuropilin-1 inhibitors
WO2007121465A3 (en) Detection of proteins from circulating neoplastic cells
CN111273012B (zh) 一种血清自身抗体联合检测的方法
WO2008019201A3 (en) Enhanced diagnostic multimarker serological profiling
WO2007111875A3 (en) Methods for diagnosing and treating kidney and colorectal cancer
WO2003087760A3 (en) Methods for detecting bcr-abl signaling activity in tissues using phospho- specific antibodies
CN101042402A (zh) 用于癌症诊断的自身抗体检测
EP0163303A3 (de) Menschliche monoklonale Antikörper gegen Zelloberflächen- oder Innenzellantigene
HK1126278A1 (en) Identification of non-small cell lung carcinoma (nsclc) tumors expressing pdgfr-alpha pdgfr(nsclc)
DK1214447T3 (da) Påvisning af pyruvatkinase-isoenzymer i fæces
WO2005114203A3 (en) Dominant b cell epitopes and methods of making and using thereof
SE9500030D0 (sv) Method of determining metastatic potential of tumor cells
ATE394676T1 (de) Verbindungen und verfahren zur diagnose von prostatakrebs
AU2002306568A1 (en) Forms of prostate specific antigens and methods for their detection
Xie et al. Expression of IL-33 in colorectal cancer and its association with clinical features